HLN Earnings Prediction
The chart below shows how HLN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, HLN sees a -1.30% change in stock price 10 days leading up to the earnings, and a +0.53% change 10 days following the report. On the earnings day itself, the stock moves by -0.22%. This data can give you a slight idea of what to expect for the next quarter's release.
HLN Key Earning Data
HLN Earnings Analysis
Positive
Organic Revenue Growth Q1 2025: Organic revenue growth of 3.5% in Q1 2025, driven by strong market share gains across key markets.
Emerging Markets Growth: Emerging markets performed particularly well, with a 6.5% growth, especially in India and China, where Sensodyne saw double-digit growth.
Product Launch Success: Successful product launches during the quarter, including Voltaren 2% strength in China and expansions in the Sensodyne clinical platform.
Revenue and Growth Analysis: Revenue of GBP2.9 billion reflected 3.5% organic growth, with 2.4% from price and 1.1% from volume mix.
Oral Health Category Growth: Oral Health category grew 6.6%, driven by strong performance in Sensodyne and Parodontax, with record market share in the UK.
Revenue Growth with Innovation: VMS revenues grew 0.9%, supported by innovation in emergency and Caltrate products, despite a decline in Centrum.
OTC Pain Relief Growth: OTC pain relief grew 2.6%, driven by Advil and Voltaren, with strong initial performance indicators for Voltaren 2% strength in China.
Respiratory Health Revenue Increase: Respiratory Health revenue increased 1.7%, aided by a stronger-than-expected cold and flu season in North America.
North America Revenue Growth: Organic revenue in North America grew 1%, with healthy consumption growth ahead of organic revenue growth.
Organic Revenue Growth: In Europe, Middle East, Africa, and Latin America, organic revenue increased 5%, with strong growth in Latin America and mid-single digit growth in Europe and EMEA.
Asia Pacific Revenue Growth: Asia Pacific saw organic revenue increase of 4.2%, with growth across all categories except Respiratory Health, and strong performance in India and China.
Unchanged Full Year Guidance: Confidence in full year guidance remains unchanged, expecting organic revenue growth of 4% to 6% and organic profit growth ahead of organic revenue growth.
Negative
Revenue Decline Analysis: Reported revenue declined 2.3% in the quarter due to a 2.9% drag from the disposals of Chapstick and non-U.S. smokers health business.
Consumer Confidence Decline: The North American market is cautious and uncertain, with consumer confidence measures at their lowest level since 2021.
Decline in Multivitamin Sales: Centrum experienced a mid-single digit decline, primarily due to a tough comparative from last year's cognitive function claims activation and overall weakness in the multivitamin category.
Organic Revenue Growth Challenges: In North America, organic revenues grew only 1%, with negative price impact largely driven by increased promotional activity relative to last year.
Respiratory Health Revenue Decline: The Respiratory Health category was impacted by a weaker cold and flu season, which affected overall revenue growth in that segment.
Foreign Exchange Impact Challenges: The foreign exchange impact on revenue and profit was a headwind of 2% on revenue and 3% on adjusted operating profit, indicating challenges in currency fluctuations.
HLN FAQs
How does HLN typically perform around its earnings report dates?
HLN's stock performance around earnings reports can vary, but historical data shows specific patterns, such as a -1.30% change leading up to the report and a +0.53% change in the 10 days following the release.
Is Haleon PLC (HLN) Q1 2025 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
HLN Earning Call Sentiment
Haleon plc (NYSE:HLN) Q1 2025 Earnings Call Transcript
HLN.N
-0.48%
